MAR 06, 2013
Avedro announced completion of a $43 million Series D round of financing to pursue its global commercialization strategy and its U.S. FDA approval strategy for corneal crosslinking procedures.
"Proceeds from this financing will allow us to execute on both our global commercialization strategy and our U.S. FDA approval strategy," said David Muller, Ph.D., CEO of Avedro. "In addition, Avedro plans to use proceeds from this financing to continue its aggressive research and development efforts. These are aimed at expanding the use of corneal crosslinking into applications such as cataract and refractive surgery which represent billion dollar market opportunities."